Browse drugs

…, 94 de novo lesions treated, with 76.6% (lesions=72) receiving Paclitaxel. Mean age 66.8 years (SD 11.53); 86.5% male. Obesity (BMI >30) …

…ducted, no agents have received approval, with the exception of valrubicin, largely attributed to factors such as the varied prior BCG exp…

…ypically delivered 5 days a week over 7 weeks concurrently with cisplatin, a regimen established through multiple randomised trials, demo…

…pports the safe omission of H2As, particularly ranitidine, from paclitaxel premedication protocols without compromising patient safety in …

…rimary objective is to determine the safety and tolerability of NP-101. The secondary objective is to assess the preliminary antitumor…

…its combination with PD-1 blockade (camrelizumab, albumin-bound paclitaxel and cisplatin/paclitaxel and cisplatin, Cam+nab-TP/TP; n=41), f…

…ns (3.6%), 20 irinotecan (2.0%), 196 paclitaxel (16.6%), and 21 trastuzumab (3.1%).Conclusion and Relevance A simulation analysis of a dose…

… container Withdrawal force (Kg) (SD) Insertion force (Kg) (SD) Oxaliplatin (100 mg/20 mL) 200 40 50 IV bag 4.22 (1.60) 5.80 (2.71) Oxalipl…

…eekly P due to intolerance and eleven patients did not complete paclitaxel: four due to severe infusional reaction, two due to myelotoxici…

…as ‘related,’ ‘most possibly related,’ or ‘possibly related’ to SSGJ-707 or tislelizumab.Abstract 1328 Figure 1Waterfall plots for SSGJ-…

…mens alone (PF vs GP) and (I–L) depict the oral regimens alone (capecitabine vs S-1); within each panel set the endpoints are, respectively,…

… in stiffness induced metabolite changes, we treated VSMCs with paclitaxel and colchicine. Our analysis revealed that paclitaxel treatment…